Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcella’s AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcella’s AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering.
Copyright West LLC. Minimum 15 minutes delayed.
Preclinical mechanistic data for constituents of AXA4010 demonstrate multifactorial potential of endogenous metabolic modulators (EMMs) on red blood cell, immune and vascular health CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 7, 2019-- Axcella Health Inc.
Appoints Laurent Chardonnet as Chief Financial Officer Promotes Heidy King-Jones to General Counsel CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 25, 2019-- Axcella Health (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address
● Covers NASH candidates AXA1125 and AXA1957 as well as other Endogenous Metabolic Modulator (EMM) compositions ● Expands Axcella’s existing composition and method of use portfolio ● Reinforces the strength of Axcella’s strategy to protect its first-mover advantage CAMBRIDGE, Mass.